



Marksans Pharma Ltd.

# Investor Presentation

Q1 FY20

9<sup>th</sup> August 2019

BSE: 524404 | NSE: MARKSANS | ISIN: INE750C01026

©2019 – Marksans Pharma Limited, All Rights Reserved.



Marksans Pharma Ltd.

# Forward looking statement

Certain statements in this presentation concerning our future growth prospects are forward looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, fluctuations in earnings, our ability to successfully integrate acquisitions, competition in our areas of business, client concentration, liability for damages in our contracts, withdrawal of tax incentives, political instability, unauthorized use of our intellectual property and general economic conditions affecting our industry

# Agenda

- Company at a glance
- Revenue composition
- History & acquisition track record
- Long-term strategy
- Research & development
- Operational review and financials
- Quarterly review - Q1 FY20
- Investment rationale



# Company at a glance

# Company overview



Marksans Pharma Ltd.

## Business Description

- Marksans Pharma Ltd., headquartered at Mumbai, is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation
- Company's key focus areas lie in the OTC & prescription drugs and it manufactures tablets (plain, enteric coated and film coated), hard & soft gelatin capsule, oral liquids and ointments
- Its manufacturing facilities are accredited by USFDA, UKMHRA and Australian TGA

## Business Model



94% of revenues comes from regulated markets




Forward-integrated business model




Presence in niche softgel segment

## Revenue Mix




## Geographic Mix



## Product Portfolio

Rs. Cr.




## Financial Snapshot

Rs. Cr.	FY19	FY18	Growth (%)
Revenue	1004.7	921.17	9.1%
EBITDA	136.8	86.9	57.5%
PAT	80.4	35.8	124.7%

# Company timeline



Marksans Pharma Ltd.






# Company structure



Marksans Pharma Ltd.



# Manufacturing capabilities



Marksans Pharma Ltd.

## Goa, India



- Manufactures oral solid tablets and soft gelatin capsules
- One of the biggest manufacturing facility in Asia, an 18,000 square feet campus

### Capacity

- 2.4 bn softgel and hard gelatin capsules per annum
- 5 bn tablets per annum

### Accreditations



## Southport, UK



- Manufactures non-sterile liquids, ointments and powder product
- Supplies to UK, West Africa & Middle East

### Capacity

- 13.6 mn bottles per annum
- 7.8 mn tubes per annum
- 5.7 mn sachets per annum

### Accreditations



## Farmingdale, USA



- Manufactures soft gels, tablets and capsules
- "Made in the USA" product offering

### Capacity

- 5 bn tablets and hard capsules per annum

### Accreditations








# Revenue composition

# The US, North America has increased its share in revenue over the past years

## REVENUE MIX



Company's business is classified under 4 heads:

- North America/ US generics
- Europe/UK generics
- Australia and New Zealand
- Rest of the world (RoW) generics (CIS, Middle Eastern, African and South-East Asian countries)

# The UK is the highest contributor to Marksans Pharma's revenues



Marksans Pharma Ltd.

**The UK**

**413.0**

Total revenues  
(₹ Cr.)

**(0.52)%**  
Y-o-y growth

**41.10%**  
Contribution to  
total revenues

## Overview of the market

- The UK pharmaceutical market is estimated to grow from ~USD 29 billion in 2015 to ~USD 43 billion by 2020, at a CAGR of 8.4%, driven primarily by a robust life sciences industry

## Company presence

- One of the top 5 Indian pharma companies in the UK
- UK business is driven by its two subsidiaries, Relonchem and Bell
- Bell has a strong OTC portfolio with 50+ products
- Relonchem's portfolio comprises high-end Rx portfolio of 100+ products

## Outlook

- Company has 50+ products in the pipeline in different stages to cater UK market
- Company is awaiting approval for ~20 MAs in the UK market

# Marksans is among a few Indian players with a proprietary marketing presence in the US



Marksans Pharma Ltd.

**The  
United  
States**

**411.5**

Total revenues  
(₹ Cr.)

**10.76%**

Y-o-y growth

**40.96%**

Contribution to  
total revenues

## Overview of the market

- The US holds over 30-40% of the global pharmaceutical market. It is expected to reach USD 190.4 billion by 2024, at a projected CAGR of 10.6% during 2019-2024, due to favoring government programs and policies

## Company presence

- In June 2015, Marksans acquired Time-Cap Labs which enabled Marksans to expand its offering in US market
- 30+ products, positioned in the niche soft gel category
- Proprietary marketing presence with 100% integration of Time-Cap Laboratories
- Strong distribution channel marketing for both OTC and Rx products

## Outlook

- Strengthen company's US operations in the coming years
- Add 4-5 new products to its portfolio during the year under review

# Australia and NZ region registered highest growth among regulated markets in FY19



Marksans Pharma Ltd.

**Australia  
and New  
Zealand**

**119.9**

Total Revenues  
(₹ Cr.)

**21.05%**

Y-o-y growth

**11.94%**

Contribution to  
total revenues

## Overview of the market

- Australia's pharmaceutical market is set to rise from >\$22.85 billion in 2016 to \$25.2 billion by 2020 registering a CAGR of 2%

## Company presence

- Marksans carries out business operations in Australia and New Zealand through its subsidiary Nova Pharmaceuticals
- Nova is one of the leading generics and private label suppliers in Australia
- Tie-ups with topmost retailers & pharmacies in Australia, like Woolworths Ltd., Coles Mayer Ltd., Aldis, Metcash and Fauldings
- Presence in key therapeutic areas

## Outlook

- Australia and New Zealand will continue to remain focus markets for the Company

# After harnessing the regulated markets, Marksans is venturing out in the emerging countries



Marksans Pharma Ltd.

**Rest of  
the world**

**60.3**

Total Revenues  
(₹ Cr.)

**70.03%**

Y-o-y growth

**6.00%**

Contribution to  
total revenues

## Overview of the markets

- ROW includes markets of South East Asia, MENA, Russian Federation & Africa

## Company presence

- Targeting four major clusters such as South East Asia, Russia and the CIS, Middle East and Africa
- In these four clusters, specific countries like Iraq, Kenya, Ukraine, Sri Lanka and Myanmar are targeted
- Started filing for approvals in these countries

## Outlook

- Company is strengthening its presence in the target markets and expects to generate 10% of the Company's revenue by FY22





Marksans Pharma Ltd.




# History & acquisition track record

# The Marksans Evolution



Marksans Pharma Ltd.



# Transformation over the years



Marksans Pharma Ltd.

## Geographic presence and growth



- Marksans commenced business with CRAMS directed at the UK and Australian markets
- The Company entered the US market in 2011-12; acquired Time-Cap Laboratories in 2015
- The Company entered the regulated Australian market with the acquisition of Nova
- The Company now has a global presence across 25 countries

## The Company was largely a manufacturing company



- Marksans commenced operations as a formulations manufacturing enterprise
- The Company entered into front-end marketing in regulated markets
- The Company was among a few Indian mid-sized companies with frontend marketing capabilities
- The Company invested in a state-of-the-art R&D facility, strengthening integration

## Wider product basket



- Marksans commenced its journey with products addressing the pain management segment
- The Company focused on high-growth areas impacted by lifestyle disorders
- The Company launched soft gelatin capsules, a niche category
- The Company now offers products across >10 therapeutic segments

## Deleveraged Balance Sheet



- Marksans reported a peak debt-equity ratio of >3 in 2008
- The Company ploughed profits into debt repayment and business expansion
- The Company repaid all long-term debt in 2014-15
- The Company's debt-equity ratio was 0.12 as on 31st March 2019



# Long-term strategy

# Strategic focus on regulated markets



Marksans Pharma Ltd.

**Marksans Pharma generates 94% of its revenues from regulated markets**



USA



UK



Australia



New Zealand

- The Company markets products in 25+ countries with the UK and the US being the largest. The Company's prominent markets, include Australia, New Zealand, Canada and several other European countries
- To expand its global footprint, Marksans entered into strategic tie-ups and acquired key players in major markets
- The US, the UK and Australian markets are empowered with regulatory approvals which enables the company to sell its products in these markets without restrictions
- Marksans is among a handful of Indian players with a proprietary marketing presence in the world's largest pharma market which is US, UK and Australia. By eliminating third parties from the value chain, company is able to generate higher margins
- The Company expects to expand in the regulated markets through integrated product development, cGMP compliance, regulatory compliance and utilization of latest technologies



# Niche formulations with few competitors



Marksans Pharma Ltd.

**Marksans is currently one of the most active Indian firms focused in Softgel segment**




- **Differentiated offerings:** Focused on softgel capsules with a view to build a differentiated set of offerings in the crowded generics market
- **Limited competition** - Given the challenges in preparing Softgel formulations plus other economic, technical and patent constraints there are not many players in this segment
- **High barriers to entry** – High capex requirements and operational costs further restrict entry
- **Selectively targeted larger markets:** Marksans has filed softgel products in all major markets including USA, UK, Europe, Canada, Australia & Russia. Of this, US alone is potentially a USD9 billion market
- **New approvals:** 6 new approvals are awaited in US
- **Manufacturing capabilities with regulatory approvals:** Marksans' Goa facility has a capacity to turn out 2.4 billion softgel capsules per annum, and has all the necessary approvals by USFDA, UKMHRA, TGA & other key regulatory authorities



# One of the few mid and small-sized pharma companies to have a forward integrated business model



Marksans Pharma Ltd.





# Research & development

# R&D continues to be the backbone of the Marksans



Marksans Pharma Ltd.



## **Marksans has India's leading R&D facilities for generic molecules:**

- The Company invested in R&D facilities to strengthen the integration
- In FY18, Marksans commissioned a state-of-the-art R&D center at Navi Mumbai, apart from one in Goa
- The new R&D facility enhanced the company's capability to accelerate product development and address a growing demand for new products in USA, UK/EU, Canada, Australia and RoW marked by faster turnaround in the generic and OTC segments
- Team of over 50 experienced scientists specializing in new drug delivery systems, formulation development and analytical development
- The company continues to maintain regulatory certifications with MHRA, TGA and USFDA, based on recent inspections
- Marksans's ability to formulate and market a drug in the shortest possible lead time has given the business a critical competitive advantage





# Operational review and financials

# Consolidated revenue crossed INR 1000 Cr. in FY19



Marksans Pharma Ltd.



## Topline driven by key geographies

- The revenue growth in FY19 was driven by increasing market share in the US & North American region

### US Region:

- Revenue from the US market grew 10.76% over FY18, contributing to ~41% of the total revenues
- Completed 100% integration with Time-Cap Laboratories in FY18
- Time Cap Labs Inc has achieved revenue of USD 57.91 Millions (FY 18-USD 52.48 Millions)




### UK Europe:

- Strong product pipeline followed by successful launches every quarter
- In Europe, UK, company targets a focused segments where competition is low
- There is a consistency in the top line generation and will be followed by existing pipeline and future launches

# Balance Sheet Trends



Marksans Pharma Ltd.









# EBITDA margin increased by 418 bps during FY19



Marksans Pharma Ltd.



## Steady growth in the profitability

- Gross margin improved from 42.68% during FY18 to 50.20% in FY19 due to better product mix in US
- The company reported a 418 bps increase in EBITDA margin in FY19. This was the result of enriching its product basket with superior products and higher improved operating efficiency across the business
- The company reported a 330 bps increase in PAT margin in FY19.



# Quarterly Review - Q1 FY20

# Growth in Profitability






Marksans Pharma Ltd.

“We have had a satisfactory quarter in terms of revenue growth while our EBITDA margins continues to be at a healthy level. We will continue to focus on our strategy of niche products that have minimal competition to drive revenue growth. UK along with US markets will drive the revenue contribution of the Company going forward.”

New product launches in the US and UK markets in the current fiscal would be key to further establishing our presence in those markets.”

**Mark Saldanha**, Managing Director, Marksans Pharma




# Business Review



Marksans Pharma Ltd.

## Revenue by market (₹ Cr.)

■ Europe, UK ■ US & North America ■ Australia & NZ ■ RoW



- Company achieved revenue of Rs. 100.9 crores from Europe, UK: Formulation business as compared to Rs. 108.24 crores achieved during last year same period registering degrowth of 6.8% during the quarter, mainly on account of currency fluctuations
- US & North America Formulation business reported growth of 12.5% to Rs. 103.6 crores during the quarter. Time Cap Laboratories Inc (company's 100% Wholly Owned Subsidiary) offers Marksans an ideal platform to further expand its operations in US
- Australia & NZ Formulation business revenue was at Rs. 30.8 crores for the quarter registering growth of 21.5% over June quarter in previous year
- Rest of World Formulation business was Rs. 11.95 crores
- Almost 95.2% of company's total revenue came from regulated markets of US, Europe, Australia and New Zealand

# Financials



Marksans Pharma Ltd.

PARTICULARS (₹ Cr.)	Q1'20	Q4'19	Q1'19	FY19	FY18
Revenue from Operations	245.03	247.41	235.25	1,000.07	912.69
Other Income	2.18	9.73	3.23	4.62	8.47
<b>Total Revenue</b>	247.21	257.14	238.49	1,004.69	921.17
Material Consumption	124.28	122.76	115.89	498.00	523.13
<b>Gross Profit</b>	120.76	124.65	119.36	502.07	389.57
<i>Gross Margin %</i>	49.28%	50.38%	50.74%	50.20%	42.68%
Operating Expenses	88.34	109.00	83.88	369.92	311.18
<b>EBITDA</b>	34.60	25.38	38.72	136.76	86.86
<i>EBITDA Margin %</i>	13.99%	9.87%	16.23%	13.61%	9.43%
Finance Cost	2.25	2.44	2.40	9.66	10.22
Depreciation and amortization	4.73	6.27	5.96	22.80	26.84
<b>Earnings Before Tax</b>	27.61	16.68	30.36	104.30	49.80
Taxes	5.13	6.82	5.48	23.87	14.00
<b>Earnings After Tax</b>	<b>22.48</b>	<b>9.85</b>	<b>24.88</b>	<b>80.44</b>	<b>35.80</b>
<i>PAT Margin %</i>	9.09%	3.83%	10.43%	8.01%	3.89%



# Investment Rationale



# Investment Rationale

- Company is widening its products portfolio in the complex and high-margin generics segment
- The US, the UK and Australian are the key Marksans' markets with all of them being now empowered with all regulatory approvals
- Marksans is among a handful of Indian players with a proprietary marketing presence in the US which is world's largest pharma market
- Marksans is among a few mid and small-sized pharma companies to have created an integrated business model by engaging R&D team in creating and filing dossiers across major markets
- The new state-of-the-art R&D center in Navi Mumbai (Nerul) is focused on formulations and novel drug delivery systems
- Company has repaid long-term loans, deleveraged the Balance Sheet and reinvested the surplus in R&D, capacity creation and brownfield expansion



Marksans Pharma Ltd.



# Marksans Pharma Ltd.

*Corporate Office:* 11th Floor Grandeur, Off Veera Desai Road,  
Opp Gundecha Symphony, Andheri (W), Mumbai 400 053. Maharashtra - India

**© 2019 Marksans Pharma Limited, All Rights Reserved.**

"Marksans Pharma" and The Marksans Pharma Logo are trademarks of Marksans Pharma Limited. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.